Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1642 1646 1671
This examiner grants 69% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18237210 | SITE-SPECIFIC QUANTITATION OF DRUG CONJUGATIONS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 19097573 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 50 SKIPPING | Final Rejection | Avidity Biosciences, Inc. |
| 19078822 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS | Non-Final OA | BPGbio, Inc. |
| 17926188 | IDENTIFICATION OF HLA-RESTRICTED PRAME PEPTIDE EPITOPES, PRAME-SPECIFIC T CELLS SUITABLE FOR "OFF-THE-SHELF" TREATMENT OF CANCER EXPRESSING PRAME | Final Rejection | Children's National Medical Center |
| 18342898 | MULTIFUNCTIONAL IMMUNE CELL THERAPIES | Final Rejection | Arcellx, Inc. |
| 17818526 | CYCLOPHOSPHAMIDE ANALOGS FOR USE AS IMMUNOGENS AND ASSAY CONJUGATES FOR AN IMMUNOASSAY OF CYCLOPHOSPHAMIDE AND IFOSFAMIDE | Non-Final OA | Becton, Dickinson and Company |
| 17887341 | SCALABLE AND FACILE CELL-MEMBRANE-COATING TECHNOLOGY FOR BOTH POSITIVELY AND NEGATIVELY CHARGED PARTICLES | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18044274 | CpG IMMUNOCONJUGATES FOR CANCER THERAPY | Non-Final OA | University of Southern California |
| 17918947 | OLIGONUCLEOTIDE CONJUGATES AND PREPARATION AND APPLICATIONS THEREOF | Non-Final OA | ACADEMIA SINICA |
| 18272050 | ANTI-DLL3 ANTIBODY-DRUG CONJUGATE | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 17759139 | VACCINATION AGAINST ANTIGENS INDUCED IN PATHOGEN-INFECTED CELLS | Non-Final OA | University of Miami |
| 18447808 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | Non-Final OA | MSD INTERNATIONAL GMBH |
| 18331966 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | Non-Final OA | INNATE PHARMA |
| 17793005 | ANTI-TROP-2 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 17596239 | ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND MEDICINAL USE THEREOF | Final Rejection | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
| 17957302 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | Non-Final OA | GENMAB A/S |
| 18282696 | ENGINEERED IMMUNE CELLS AND USES THEREOF | Non-Final OA | Nanjing Legend Biotech Co., Ltd. |
| 16964965 | ANTIBODY-DRUG CONJUGATES THAT TARGET DLK1 AND USES THEREOF | Non-Final OA | Y-Biologics, Inc. |
| 18001374 | TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR RECEPTOR A2 (EPHA2) | Non-Final OA | BicycleTx Limited |
| 18258343 | Therapeutic RNA for Treating Cancer | Non-Final OA | BioNTech SE |
| 18252818 | PHARMACEUTICAL FORMULATION | Non-Final OA | AstraZeneca UK Limited |
| 18254941 | ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF | Non-Final OA | QURE BIOTECHNOLOGY (SHANGHAI) CO., LTD. |
| 18036142 | NEW TYPE II COLLAGEN BINDING PROTEINS | Non-Final OA | Navigo Proteins GmbH |
| 18247056 | PREPARATION METHOD FOR BIS-SUBSTITUTED BRIDGING ANTIBODY-DRUG CONJUGATE | Non-Final OA | JIANGSU MABWELL HEALTH PHARMACEUTICAL R&D CO., LTD. |
| 18012710 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | Final Rejection | SAPREME TECHNOLOGIES B.V. |
| 18087678 | METHODS FOR THE PREPARATION OF LINKER PAYLOAD CONSTRUCTS | Non-Final OA | SYNAFFIX B.V. |
| 17812160 | CONJUGATES OF ANTIBODIES AND IMMUNE CELL ENGAGERS | Non-Final OA | SYNAFFIX B.V. |
| 18156709 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | Non-Final OA | Hangzhou DAC Biotech Co., Ltd. |
| 17622360 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Non-Final OA | Hangzhou DAC Biotech Co., Ltd |
| 18062494 | DRUG CONJUGATES COMPRISING ANTIBODIES AGAINST CLAUDIN 18.2 | Non-Final OA | TRON-Translational Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy